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Abstract
There is a rising interest in a balanced and varied
women’s diet not only preconceptionally but also during
pregnancy and in the breastfeeding period in order to
reduce fetal, neonatal, and maternal risks. A decreased
intake of omega 3-fatty acids (FA) or deficiencies of
micronutrients are a global health problem, not only in
developing countries, where micronutrient-rich food and
fortified aliments are often not available, and also in the
industrialized world. In contrast to data about the daily
periconceptionally intake of folate acid that has been
shown to reduce substantially the occurrence and recur-
rence of neural tube defects (NTD), the benefit of other
micronutrients is less determinant.
Deficiencies of omega 3-FA may be a contributing factor
for severe complications in pregnancy and postpartum.
A meta-analysis for the role of omega 3-FA in preeclamp-
sia and maternal postpartum depression is less consis-
tent, some meta-view’s results differ substantially or are
even contradictory to large observational studies. Further
well-designed studies are warranted. A personal inter-
view and counseling concerning the daily diet should be
integrated in the preconceptional and in the antenatal
care and an individual supplementation should be
offered, if indicated.
Keywords: Dietary supplements; fatty acids; omega-3;
pregnancy; vitamins.
Role of omega 3-FA in gestation
Nutrition habits among women in industrialized
countries
Low pre-pregnancy body mass index (BMI) as well as low
energy intake during pregnancy, such as seen in famine
periods, is associated with adverse pregnancy outcome
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like preterm delivery, intrauterine growth restriction
(IUGR) and maternal delivery complications w13x. How-
ever, during the last 10–15 years, the BMI has increased
to values over 30 kg/m2 in 33.4% of women in the USA
or in 9.2% of women in Switzerland, which has also influ-
enced pregnancy outcome by increased rates of macro-
somia, cesarean section, the rate of gestational diabetes,
preeclampsia, preterm delivery and stillbirth w6x. In 2006,
worldwide, more than a billion people are overweight
(BMI)25 kg/m2), more than 300 million of them obese
(BMI)30 kg/m2) compared to 800 million that are under-
weight (BMI-19 kg/m2) w27x.
Fat intake worldwide has increased substantially, main-
ly consisting of the saturated and trans fatty acids, fol-
lowed by a decline of polyunsaturated fatty acids (PUFA)
and especially of omega 3-FA of about 80%. Measure-
ments of human milk concentrations of decosahexaenoic
acid (DHA) showed a decrease by 50% in Canada and
Australia w23x. At the same time, the intake of omega 6-
FA increased and the dietary ratio of omega 6–3-FA
changed from the earlier 2:1 to the current 10–16:1 w36x.
One explanation for a decline in omega 3-FA rich diet –
amongst other factors – is an increasing concern from
environmental pollutants like heavy metals that are
known to accumulate in certain fish species. Fish that
contain high levels of mercury, polychlorinated biphenyls
(PCBs) or dioxin are mostly the long living and predatory
fish types like tilefish, swordfish, shark and king mack-
erel. This has led to warnings from national organizations
like the Food and Standard Agency (FSA) to reduce fish
consumption, the richest source of omega 3-FA. After the
release of this advice the fish consumption in the USA
decreased continually for all fish groups. Unfortunately
this included canned tuna fish, which contains small fish,
and has far lower mercury levels. Although different
national guidelines reinforced a weekly intake of two por-
tions of fish from different sources, the trend for avoiding
fish and, therefore, omega 3-FA continues w28x.
Demand of omega 3-FA in pregnancy and lactating
period
DHA concentration in maternal plasma increases early in
pregnancy (approximately 40% in the first and second
trimester) compared to pre-pregnancy levels. The DHA
concentration subsequently depletes as the demand of
the fetus increases in the third trimester w22x. The
increase in maternal plasma cannot be explained by an
increased intake, but is caused by mobilization from
maternal stores built up before pregnancy. If the mother
is breastfeeding after delivery, the maternal blood con-
S20 Ho¨sli et al., Role of omega 3-fatty acids and multivitamins in gestation
Article in press - uncorrected proof
Table 1 The deficit of omega 3-fatty acids has the potential to
influence both maternal and fetal health during pregnancy.
Maternal health Fetal development
Preeclampsia, eclampsia Preterm delivery
Gestational hypertension Birth weight
Gestational diabetes Prolongation of pregnancy
Postpartum depression IUGR
Fetal neurological and visual
development
centration of DHA rapidly decreases by up to 20% under
normal value and returns after weaning. If the baby is
bottle-fed, the DHA concentration soon after delivery
returns to the pre-pregnancy level.
Several influences of omega 3-FA on the pregnant
women and the fetus have been assessed in obser-
vational studies analyzing maternal fish intake and in ran-
domized controlled studies with the supplementation of
fish oil (Table 1).
Influence of omega 3-FA on preeclampsia
Maternal blood pressure responds to fish oil supplemen-
tation in a dose dependent manner. The result of a meta-
regression analysis of randomized controlled trials (RCT)
showed that the systolic blood pressure decreased by
2.1 mmHg (95% CI 1.0–3.2) and the diastolic blood pres-
sure by 1.5 mmHg (95% CI 1.0–2.2) in a non pregnant
population with a median dose of 3.7 g/d fish oil mainly
comprising eicosapentanoic acid (EPA)/DHA w16x.
Preeclampsia is one of the most common serious
complications in pregnancy, affecting 5–7% of pregnant
women and is one of the leading causes for maternal
morbidity and mortality. As preeclampsia is a state of
increased oxidative stress and a reduced antioxidant
response there are several theoretical rationales for the
use of omega 3-FA as antioxidants:
1. Inhibiting the prostaglandin synthesis and exhibit anti-
oxidant properties w29x
2. Decreasing platelet and leukocyte reactivity
3. Vasodilatation
Epidemiological observational studies confirmed that
Inuit women with a high consumption of fish had a lower
blood pressure at the end of pregnancy and a lower inci-
dence of pregnancy induced hypertension w11x. Cord
blood phospholipids fatty acid analyses confirmed higher
levels of EPA, a fatty acid enriched in fish and sea mam-
mals w17x. In a cross sectional study where erythrocyte
omega 3- and 6-FA as biomarkers were measured, wom-
en with the lowest levels of omega 3-FA were 7.6 times
more likely to have pregnancies complicated by pre-
eclampsia as compared with women with the highest lev-
els of omega 3-FA after adjusting for confounders (95%
CI 1.4–40.6). A 15% increase in the ratio of omega
3–6-FA was associated with a 46% reduction in risk of
preeclampsia (ORs0.54; 95% CI 0.41–0.72) w42x. As
omega 3-FA might have both antioxidative and pro-oxi-
dative properties, depending on experimental conditions,
dosage and background of the diet, Shoji et al. w35x doc-
umented in a double blind RCT that supplementation of
500 mg DHA and 150 mg EPA combined with Vitamin A,
E, D and C in the required amount during pregnancy did
not enhance oxidative DNA damage and lipid peroxida-
tion in 23 pregnant women from 20 weeks of gestation
to delivery. RCT on omega 3-FA and preeclampsia, how-
ever, failed to confirm a significant risk reduction.
Makrides et al. w26x summarized the data from 6 RCTs
including 2783 women. The relative risk for developing
preeclampsia after intake of marine fish oil or supple-
mentation with any prostaglandin precursor showed in
four trials with 1683 women and a singleton pregnancy,
a trend to lower the risk for preeclampsia but no clear
difference in the relative risk of preeclampsia between the
two groups: RR 0.86 (95% CI 0.59–1.27). The studies
differed in the amount of DHA intake between 133 mg/d
and 3 g/d, the most commonly used dose was 2.7 g/d
PUFA (1.5 g EPA and 1 g DHA) corresponding to 300 g
of cooked salmon daily. Supplementation started after 16
weeks of gestation. There was no difference in the per-
centage of bleeding complications before or after deliv-
ery between the supplemented and the control group.
Thirteen percent had a blood loss over 500 mL in the fish
oil group vs. 8% in the olive oil group. The only maternal
side effects were belching and an unpleasant taste, RR
3.55 (95% CI 2.78–4.52). The authors concluded that
there is not enough evidence to supplement women with
fish oil or another prostaglandin precursor in order to
reduce the risk for preeclampsia.
Another meta-analysis of 6 RCTs with 1278 low risk
participants w39x did not find, in a subgroup of 328 wom-
en, evidence that supplementation with omega 3-FA/
DHA (1000 mg/d DHA vs. 200 mg/d DHA) influenced the
rate of preeclampsia or eclampsia (RRs0.73; 95% CI
0.22–2.37). The trials differed in the beginning of supple-
mentation as early as 15 weeks or as late as 30 weeks.
Influence of omega 3-FA on postpartum depression
Postpartum depression (PPD) affects between 5 and
20% of parturients. However, it is labeled as the most
under-recognized, under-diagnosed, and under-treated
obstetrical complication. PPD influences adversely the
mother-child relationship, infant development and well-
being.
Parturients provide an excellent opportunity to exam-
ine the relation between concentration of omega 3-FA
and the prevalence of PPD because omega 3-FA are
transferred from mother to child through breast milk.
Hence new mothers are more likely to be depleted in
omega 3-FA. DHA has been proposed in PPD as pro-
phylaxis or treatment alone or adjunct to antidepressive
Ho¨sli et al., Role of omega 3-fatty acids and multivitamins in gestation S21
Article in press - uncorrected proof
therapy. The assumed physiologic mechanisms of ome-
ga 3-FA affecting postpartum depression are: w15x
1. Effects on serotonergic and dopaminergic neuro-
transmission
2. Alteration of protein phosphorylation and impact upon
protein kinase
3. Immunological effects
4. Vagal mechanisms
5. Heightened dendritic arborization and synapse
genesis
6. Regulation of gene expression
In observational studies, low levels of omega 3-FA
measured in blood samples correlated with clinical
depression, depressed mood and PPD. In general, these
studies report a shift away from omega 3-FA towards
omega 6-FA in depressed patients w37x. In four of seven
double-blind RCTs performed in a general population,
depression was significantly improved upon treatment
with at least 1 g/day of EPA. It remained unclear whether
omega 3-FA supplementation is effective independently
of antidepressant treatment, or only for those with abnor-
mally low concentrations of these PUFAs w37x.
Tanskanen et al. w40x observed a significant relation-
ship between infrequent fish consumption and depres-
sive symptoms only among women but not in men. A
multinational ecological study confirmed that both higher
concentrations of DHA in mothers’ milk (rsy0.84,
P-0.0001, ns16 countries) and greater seafood con-
sumption (rsy0.81, P-0.0001, ns22 countries) predict
a lower prevalence rate of PPD in simple and logarithmic
models, respectively w19x. The highest prevalence for
PPD was 24.5% in South Africa and the lowest was 2.0%
in Japan. A limitation was that confounding factors
(young maternal age, low socioeconomic status, smok-
ing, etc.) were not uniformly available.
The self report of 13,799 women with lower seafood
intake at 32 weeks’ gestation was associated with
approximately doubling the risk of severe depression in
pregnancy and postpartum w20x. One RCT investigated
the effect of 0.2 g/d DHA on PPD in 138 women. Llorente
et al. w25x failed to observe an association, although DHA
supplementation, given after delivery for four months,
prevented the usual decline in plasma phospholipids
DHA content of breastfeeding mothers. The limitations of
this trial were the low dosage of DHA, treatment without
EPA, and the fact that not all but only 6.7% of partici-
pants were diagnosed with clinical depression.
International recommendations for omega 3-FA
intake
Evidence exists that the required intake of omega 3-FA
does not meet requirements and that omega 3-FA does
have a potential importance for pregnancy and the post-
partum period. Although current available data from RCT
are not sufficient to recommend general supplementa-
tion, several organizations and scientific groups have
made recommendations for fish consumption or supple-
mentation for pregnant and lactating women:
• Food standard Agency (FSA)/Scientific Advisory Com-
mittee on Nutrition (SACN) 2003, UK: regular con-
sumption of oily fish like fresh tuna, mackerel, sardines
and trout, up to two portions/week, avoid shark,
swordfish, marlin w2, 34x.
• Food and drug administration (FDA)/Environmental
protection agency (EPA) 2004: two average meals/
week of a variety of fish and shellfish that are lower in
mercury (shrimps, canned tuna, salmon, pollock, cat-
fish) and not more than one tuna steak (175 g)/week
w14, 41x.
• European community (EC) 2004: not more than 100 g
of fish like swordfish, shark, marlin, and pickerel per
week. Not more than two portions of tuna fish per
week w12x.
• Swiss health administration (BAG) 2006: oily fish con-
sumption 1 to 2 times per week (280–300 g/week), fish
with low mercury concentrations like trout, redfish,
whitefish, sardines, white halibut. No consumption of
swordfish, marlin, shark, high dioxin concentrations in
Baltic herring and Baltic salmon w3x.
• Perilip 2006: Maternal dietary intake of fatty fish or oils
providing DHA of at least 200 mg/d up to 1 g/d or
2.7 g/d of PUFA w44x.
It is recommended that only purified fish oil should be
consumed. The quality of fish oil has to be tested for
toxic contaminations like heavy metal, dioxins, PCBs.
Hormones and any other contaminants should be
absent.
Micronutrients
Multiple micronutrient supplementations for women
during pregnancy
The combination of multiple micronutrients in a single
pharmaceutical form has been suggested to be a simple
and cost-effective way to achieve multiple benefits w1x.
Studies assessed the issue if multiple-micronutrient sup-
plementation during pregnancy may have a benefit for
mother and fetus. In a recently published Cochrane issue
w18x, including nine trials with over 15,000 patients, mul-
tiple-micronutrient supplementations, compared with
micronutrients containing two or less ingredients or no
supplementation/placebo, resulted in a statistically
significant reduction in the number of low birth weight
neonates RR 0.83; 95% CI 0.76–0.91, small-for-gesta-
tional-age babies (RR 0.92; 95% CI 0.86–0.99) and
maternal anemia (RR 0.61; CI 0.52–0.71). But the authors
concluded that these results lost statistical significance
when multiple-micronutrients were compared with iron
folic acid supplementation. Furthermore, no statistically
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Table 2 Special groups that are at risk for undernourishment
for micronutrients.
• Overweight
• Migrants
• Vegetarian and Vegans, culture based diet
• Smokers
• Multiple pregnancy
• Chronic disease (e.g., HIV infected women)
• Short birth interval
• Adolescents
• Diminished exposure to sunlight (wearing a veil or dark
pigmentation)
significant differences could be shown for the rates of
preterm deliveries and overall perinatal mortality. How-
ever, different dose regimens were used. Table 2 includes
data from women with a higher risk to be undernourished
with micronutrients.
Supplementation with different vitamins for
preventing miscarriage
Supplements, such as folate, have been recommended
for patients at risk of spontaneous miscarriage, associ-
ated with elevated homocysteine levels. These are sign-
ificantly elevated in patients with a history of two or more
consecutive miscarriages w10x. As a consequence, a sup-
plementation with folate may decrease the risk. Further-
more, oxidative stress, leading to elevated levels of
reactive oxygen molecules and lowered levels of anti-
oxidants, has been linked to spontaneous and recurrent
miscarriage w24x. However, the use of supplements in
pregnancy needs to be supervised, especially regarding
safety of the ingredients. This fact is particularly import-
ant for the intake during the first trimester, where there
exists an increased potential for teratogenicity. A terato-
genic potential is noted for high maternal levels of pre-
formed vitamin A (retinoic acid), resulting in an increased
risk of spontaneous miscarriages and fetal cerebral and
cardiac malformations. In contrast, a teratogenic effect
of other vitamins has not been reported. Rumbold
et al. w32x reported the possible benefit of vitamin sup-
plementation for preventing miscarriage. The authors
combined data of 35,812 women. No significant differ-
ence was observed between women taking any vitamins
compared with controls for total fetal loss (RR 1.05, 95%
CI 0.95–1.15), early or late miscarriage (RR 1.08, 95% CI
0.95–1.24) or stillbirth (RR 0.85, 95% CI 0.63–1.14). In
four trials with 5580 patients, the authors observed that
patients taking any type of vitamin(s) were less likely to
develop preeclampsia (RR 0.68, 95% CI 0.54–0.85) and
were more likely to have a multiple pregnancy (RR 1.38,
95% CI 1.12–1.70) compared with controls. The authors
conclude that vitamin supplements taken periconcep-
tionally and in the first trimester, do not significantly
reduce the risk for miscarriage or stillbirth. However, the
intake of vitamin supplements may be associated with a
lower rate of preeclampsia and a higher rate of multiple
pregnancies.
Multivitamins or folic acid for the primary prevention
of birth defects
The periconceptional use of folic acid alone or in com-
bination with other supplements is effective for the pri-
mary prevention of neural-tube defect. A risk reduction
of the occurrence and recurrence rate of neural tube
defects (NTDs) has been demonstrated w4x. Furthermore,
multivitamins, as well as folic acid alone, can prevent
some congenital cardiovascular malformations. It be-
comes apparent that many women do not consume
enough folic acid. The National Diet and Nutrition Survey
showed that 84% of women fail to achieve the Reference
Nutritient Intake for folic acid w21x. However, this state-
ment cannot be assessed without taking the sociological
and cultural background into account.
One study assessed the question if multivitamins con-
taining 0.4–0.8 mg of folic acid were more effective for
the reduction of neural-tube defects than higher doses
of folic acid, including pooled data of two Hungarian trials
using a multivitamin containing 0.8 mg folic acid and the
data of the Hungarian Case-Control Surveillance of Con-
genital Abnormalities using a high dose of folic acid w8x.
The study demonstrated that multivitamin preparations
containing 0.4–0.8 mg of folic acid were more effective
for the reduction of NTDs than a high dose of folic acid.
Similarly, only multivitamins were able to reduce the prev-
alence of congenital obstructive urinary malformations,
limb deficiencies and congenital pyloric stenosis. How-
ever, folic acid was effective in reducing the rate of rectal/
anal stenosis/atresia, and a high dose of folic acid
reduces the rate of orofacial clefts. These findings are in
line with other studies demonstrating that the pericon-
ceptional multivitamin and folic acid supplementation
reduces the overall occurrence of congenital abnormali-
ties in addition to the previous demonstrated effect on
NTDs w9x.
Supplementation with vitamins and preeclampsia
A double-blind trial of 283 pregnant women with a pre-
vious preeclampsia or abnormal blood flow to the pla-
centa assessed the effect of vitamin E (400 IU/d) plus
1000 mg vitamin C versus placebo on plasma markers
of vascular endothelial activation and placental insuffi-
ciency and the occurrence of preeclampsia. The study
showed a possible benefit in the prevention of pre-
eclampsia in women at increased risk of the disease w7x.
These promising data are in contrast to two recently pub-
lished multicenter trials. Rumbold et al. w33x included
1877 nulliparous women between 14 and 22 weeks’ ges-
tation. A total of 935 patients were randomly assigned to
the vitamin group with 1000 mg of vitamin C and 400 IU
of vitamin E. The study showed no significant differences
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between the vitamin and placebo groups regarding the
risk of preeclampsia (6.0% and 5.0%, respectively; RR
1.20; 95% CI 0.82–1.75), but a trend towards a higher
rate of death or serious outcomes in the infant (9.5% and
12.1%; RR 0.79; 95% CI 0.61–1.02), or towards having
an infant with a birth weight below the 10th percentile
(8.7% and 9.9%; RR 0.87; 95% CI 0.66–1.16) in the vita-
min group. The authors concluded that a supplementa-
tion with vitamins C and E during pregnancy does not
reduce the risk of preeclampsia in nulliparous women.
However, the accompanying editorial stated that this trial
was powered to detect a reduction of 50% or more in
the risk of preeclampsia and that the possibility of a
smaller benefit could not be ruled out.
A recently published trial with 2400 high-risk pregnant
patients did not show a reduced incidence after treat-
ment with vitamin C (1000 mg) and vitamin E (400 IU) in
a high risk population w31x. The results may be biased by
the inhomogeneity of the study population with singleton
and multiple pregnancies, patients with diabetes, chronic
hypertension or antiphospholipid syndrome.
Another recent study, including 1835 pregnant women
enrolled in the Pregnancy Exposures and Preeclampsia
Prevention Study, showed that a regular use of multivi-
tamins is associated with a 45% reduction of preeclamp-
sia compared with non use (OR 0.55, 95% CI 0.32–0.95)
w5x. However, overweight before conception modified this
effect. After adjustment for this variable, lean multivitamin
users (BMI-25) had a 71% reduction in preeclampsia
risk compared with lean nonusers (OR 0.29, 95% CI
0.12–0.65). In contrast, there was no relation between
multivitamin use and preeclampsia among overweight
women (BMI)25) (OR 1.08, 95% CI 0.52–2.25).
Iron deficiency
At least 50 million pregnant women in low-income coun-
tries are anemic, primarily due to iron deficiency w38x.
Iron-deficient anemia, the late manifestation of chronic
iron deficiency, is thought to be the most common nutri-
ent deficiency among pregnant women w43x. Anemia in
pregnancy is diagnosed if hemoglobin (Hb) concentration
is lower than 110 g/L during the first and third trimesters
or lower than 105 g/L during the second trimester,
according to recommended U.S. Centers for Disease
Control and Prevention (CDC) and World Health Organi-
zation (WHO) cut-off points.
Forty trials, involving 12,706 women, were included in
the relevant Cochrane review w30x. Iron deficiency results
in anemia, which may increase the risk of death from
hemorrhage after delivery, although its effects on fetal
development and birth outcomes are still unclear.
The data suggest that daily antenatal iron supplemen-
tation increases hemoglobin levels in maternal blood
both antenatally and postnatally. It is difficult to quantify
this increase due to a significant heterogeneity between
the studies. Women who receive daily antenatal iron sup-
plementation are less likely to have iron deficiency and
iron-deficiency anemia at term as defined by the current
cut-off values. Side-effects and hemoconcentration are
more common in women who receive daily iron supple-
mentation. No differences were evident between daily
and weekly supplementation with regards to gestational
anemia.
Conclusion
The adequate supply with micronutrients and omega 3-
FA is often not fulfilled as well in the industrialized as in
low income countries. Although awareness for the pre-
conceptional use of MV and the risk reduction for fetal
anomalies is high, the appropriate pre-conceptional use
is low. Obstetricians should acquire more knowledge
related to nutrition and information about dietary habits.
Especially, intake of omega 3-FA should be considered
early in the antenatal care. Regarding the micronutritient
status of a pregnant woman, a personal interview and
biochemical tests during antenatal care visits can reveal
micronutritient deficiencies. After counseling, these
should be corrected with an individual supplementation.
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